A study to evaluate Chemotherapy Plus Osimertinib against Chemotherapy Plus Placebo in patients with non-small cell lung cancer (NSCLC)

Trial Identifier: D5162C00042
Sponsor: AstraZeneca
Collaborator:
Parexel
NCTID:: NCT04765059
Start Date: September 2021
Primary Completion Date: December 2024
Study Completion Date: December 2024
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AT Graz, AT, 8036
AT Klagenfurt, AT, 9020
AT Linz, AT, 4020
CN Beijing, CN, 100005
CN Beijing, CN, 100142
CN Ganzhou, CN, 341000
CN guangzhou, CN, 510080
CN Hohhot, CN, 010017
CN Jinan, CN, 250013
CN Linyi, CN, 276000
CN shenyang, CN, 110001
CN Tianjin, CN, 300060
CN Wuxi, CN, 214023
CN Xiangfan, CN, 441021
CN Zhengzhou, CN, 450052
CN Zhengzhou City, CN, 450008
DE Berlin, DE, 12351
DE Hannover, DE, 30625
DE Hessen, DE, 61231
DE Karlsruhe, DE, 76137
DE Köln, DE, 51109
DE Köln, DE, 50937
DE München, DE, D-80336
DE Ulm, DE, 89081
ES Alicante, ES, 03010
ES Barcelona, ES, 08907
ES Cáceres, ES, 10003
ES Cordoba, ES, 14004
ES León, ES, 24071
ES Madrid, ES, 28040
ES Málaga, ES, 29010
ES Murcia, ES, 30008
ES Oviedo, ES, 33011
ES Palma de Mallorca, ES, 07010
ES Sevilla, ES, 41013
ES Valencia, ES, 46010
IL Beer Sheva, IL, 84101
IL Jerusalem, IL, 9103102
IL Jerusalem, IL, 9112001
IL Kfar Saba, IL, 4428164
IL Petah Tikva, IL, 494142
IL Tel Aviv, IL, 6423906
IL Tel Hashomer, IL, 52621
IT Firenze, IT, 50134
IT Meldola, IT, 47014
IT Messina, IT, 98158
IT Napoli, IT, 80131
IT Padova, IT, 35128
IT Palermo, IT, 90146
IT Roma, IT, 00168
IT Terni, IT, 05100
IT Verona, IT, 37124
US, MA Boston, MA, US, 02215
US, MA Boston, MA, US, 02114
US, MA Newton, MA, US, 02462
US, MD Silver Spring, MD, US, 20910
US, MN Minneapolis, MN, US, 55407